Brand Reference: Trental
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pentoxifylline Controlled-Release RxNorm Concept ID | 8031 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1950 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $56.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $9.40 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $12.00 / mo | 14 Zero-PHI Verified Patient Logs |
Non-selective phosphodiesterase inhibitor that elevates erythrocyte intracellular ATP and cAMP to increase red-blood-cell membrane flexibility through 5-micron capillaries, lowers plasma fibrinogen viscosity, and suppresses TGF-beta1/TNF-alpha microvascular fibrosis.
Classified under Hemorheologic Methylxanthine Erythrocyte Deformability & TNF-Alpha Inhibitor (Rx), Pentoxifylline Controlled-Release exhibits a $46.60/month gap between standard U.S. retail cash counters ($56.00) and verified direct-to-patient routing ($9.40) anchored to $0.1950 CMS unit cost.
Pharmacokinetic profiling of Pentoxifylline Controlled-Release demonstrates an elimination half-life of 0.8 hours parent / 1.6 hours active M1 & M5 / 8-hour ER matrix with ~95% absorbed (20%–30% post-first-pass parent + high active M1) systemic bioavailability; clearance proceeds via erythrocyte & hepatic keto-reductase conversion to active 5-hydroxyhexyl m1, reaching clinical onset within 2–6 weeks microcirculatory claudication & fibrosis improvement.
Titration schedules for Pentoxifylline Controlled-Release (400 mg ER PO TID with meals (or BID if GI sensitive)) require excluding recent cerebral or retinal hemorrhage; severe methylxanthine caffeine/theophylline intolerance; real-world patient logs highlight dyspepsia without food (17% of reports), dizziness (8% of reports) alongside a 81.70% Worth-It consensus.
Across 14 verified cash-pay logs, Pentoxifylline Controlled-Release achieves a 81.70% Worth-It rating with out-of-pocket spend averaging $12.00/mo versus $56.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 400 mg ER PO TID with meals (or BID if GI sensitive) for Pentoxifylline Controlled-Release; monthly out-of-pocket dropped to $8.27 compared with $56.00 retail.
Completed 10 weeks on Pentoxifylline Controlled-Release (400 mg ER PO TID with meals (or BID if GI sensitive)). Zero notable side effects on steady dosing.
Consistent biomarker response on 400 mg ER PO TID with meals (or BID if GI sensitive) Pentoxifylline Controlled-Release sourced via Cash Clinic ($10.90/mo cash pay without insurance prior authorization).